Q-omics provides the consensus-scored HTR3C2P profile across patient tissues and cancer cell-line models. HTR3C2P expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HTR3C2P is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, HTR3C2P RNA expression shows 11,015 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where HTR3C2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HTR3C2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HTR3C2P survival associations across molecular data types. HTR3C2P RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HTR3C2P RNA expression–survival associations across cancer types. High HTR3C2P expression shows unfavorable associations in KIRC, MESO, THCA, PAAD and LUAD, but favorable associations in LAML. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HTR3C2P RNA expression.
This table summarizes HTR3C2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for HTR3C2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HTR3C2P shows lower tumor expression in THCA. The THCA box plot shows higher HTR3C2P RNA expression in normal versus tumor tissue (log2 FC = −0.051, t-test p < 0.001).
This table shows molecular features associated with HTR3C2P in patient tissues and cancer cell lines. In patient samples, HTR3C2P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
